The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project.
 
Seth P. Lerner
Consulting or Advisory Role - BioCancell; Genentech/Roche; Merck; Nucleix; Oncogenex; Sitka; Theracoat; Vaxiion
Research Funding - Endo Pharmaceuticals; FKD Therapies; Tengion
 
Jaegil Kim
No Relationships to Disclose
 
David J. Kwiatkowski
No Relationships to Disclose
 
Gad Getz
No Relationships to Disclose
 
John N. Weinstein
No Relationships to Disclose
 
Andrew Cherniack
No Relationships to Disclose
 
Guangwu Guo
No Relationships to Disclose
 
Rehan Akbani
No Relationships to Disclose
 
Katherine A. Hoadley
No Relationships to Disclose
 
William Y. Kim
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Johnson & Johnson; Medivation; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier
 
Gordon Robertson
No Relationships to Disclose
 
Andrew J. Mungall
No Relationships to Disclose
 
Toshinori Hinoue
No Relationships to Disclose
 
Peter W. Laird
No Relationships to Disclose
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Dean F. Bajorin
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Genentech; Merck; Novartis; Roche; Roche/Genentech
Research Funding - Amgen (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck; Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Donna E. Hansel
Consulting or Advisory Role - Cell Biosciences; Genentech
 
Chad J. Creighton
No Relationships to Disclose